Coronaviruses roadmap:
Vaccines
Research roadmap for coronavirus vaccine development
Download 202402 Draft Coronavirus Vaccine research roadmap Final10
Expression system
Expression system
Research Question
- What are we trying to achieve? Development of efficient expression system for recombinant viral glycoproteins, live attenuated virus cell lines or viral vector production
- What is the problem? Deciding suitable expression systems for different vaccine platforms, their efficiency and whether they would work in different animal models, particularly when developing a new animal model.
Research Gaps and Challenges
- Universality: Not all viral glycoproteins will be as easily expressed, stabilised, pseudotyped, and mono-serotypic as SARS2 spike. We need to turn our attention to more difficult orthologues whose expression and immunization does not always lead to the provision of immunity, e.g. Lassa, HIV. Will spike stabilization strategies like HexaPro be applicable to all coronaviruses?
- Cell culture system: Choosing the appropriate cell culture (mammalian, yeast, bacteria, plant-based, insect) system to obtain best expression, optimal yield, purity, minimise contaminants etc
- Immune response: Understanding whether different expression systems will result in differential immune response, and whether this is sufficient to provide protection, stop onward transmission etc. This is also important when considering comparing different coronavirus vaccines made using different expression systems – what do we define as a correlate of protection?
- Cost: Mammalian expression systems are more costly than e.g., insect expression systems – is one preferable over the other when generating animal vaccines? More vaccines could be produced, the requirement for purity is less stringent than in human vaccines, and it is cheaper to make animal vaccines
- Yield: Will one expression system return a greater yield of vaccine over another? Is this as important if the vaccine is not needed urgently? An economical vaccine that requires less investment and can be easily scaled up is of highest priority when designing animal vaccines
Solution Routes
- Finding appropriate cell or tissue cultures to study coronaviruses in vitro that best mimic in vivo replication
- Alternative methods: Use of ex-vivo tissue and organoid cultures from natural host species when possible
- Availability: Broaden access to validated expression systems that are compatible with the first steps in clinical trial
Dependencies
- There needs to be a better understanding of coronavirus glycoprotein biology to recognise which expression systems may be appropriate for spike without continuous rounds of trial and error, particularly the more difficult orthologues
State Of the Art
- Modified live attenuated vaccine for PEDV generated through passage through Vero cells
- PEDV recombinant vaccines – mammalian and yeast expression system o Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein – PMC (nih.gov) o S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen – PMC (nih.gov) −
- Corn-based delivery system for TGEV o A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine – PMC (nih.gov)
- Bacteria expression system for PEDV and TGEV : o Construction of a bivalent DNA vaccine co-expressing S genes of transmissible gastroenteritis virus and porcine epidemic diarrhea virus delivered by attenuated Salmonella typhimurium – PubMed (nih.gov)
Projects
What activities are planned or underway?
Differential susceptibility of SARS-CoV-2 in animals : Evidence of ACE2 host receptor distribution in companion animals, livestock and wildlife by immunohistochemical characterisation
Planned Completion date 26/07/2021
Participating Country(s):
Netherlands
Veterinary Biocontained facility Network for excellence in animal infectiology research and experimentation
Planned Completion date 28/02/2023
Participating Country(s):
Europe